Renexxion Ireland Ltd
Cat Pearson has a diverse work experience in the healthcare industry. Cat is currently the Chief Operating Officer at Renexxion Ireland Ltd, a position they started in July 2021. Prior to that, they worked at Virgin Care as the Senior Business Development Manager from January 2018 to July 2021. Before their role at Virgin Care, Cat worked at Nuffield Health from 2008 to 2017. Cat held various positions at Nuffield Health, including Business Development Manager, NHS and Commercial Engagement Manager, and Capacity and Performance Lead. In these roles, they were responsible for driving growth opportunities, engaging with stakeholders, managing contracts, marketing services, and optimizing operational efficiency.
Cat Pearson attended the University of Birmingham from 2004 to 2007, where they earned a BA in English Literature and American Studies. Prior to their time at the university, they also attended The Queen's School in Chester. Further details about their degree or field of study are not provided.
This person is not in any teams
This person is not in any offices
Renexxion Ireland Ltd
Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).